A Phase I/II Study of Ganetespib in Combination With Doxorubicin
Status:
Terminated
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase I/safety dose expansion study of the combination of the drug ganetespib and
doxorubicin in patients with advanced solid tumors. The purpose of the Phase I part of the
study is to determine the recommended phase II dose of ganetespib when given in combination
with doxorubicin. The recommended Phase II dose determined at the end of the dose escalation
phase will be used to conduct a safety dose expansion phase in relapsed/refractory small cell
lung cancer to determine if there is a signal of efficacy in this population.